Published in Lab Law Weekly, December 15th, 2006
For the third quarter of 2006 Amarin reported a net loss of $7.3 million, or $0.09 per share, compared with an adjusted net loss of $5.0 million, or $0.10 per share, in the third quarter of 2005. The increase in net loss primarily reflects Amarin's substantial investment in research and development, particularly in the two fully-enrolled phase III trials with Miraxion in Huntington disease. The net loss for the comparative periods ended September 30, 2005 have been adjusted to reflect the adoption of Financial Reporting Standard 20 (FRS 20) which became effective on January 1,...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.